Pfizer, Roche, AstraZeneca: Emerging Markets Earnings Roundup (Part 3)
This article was originally published in PharmAsia News
Executive Summary
Year-end and Q4 pharma earnings results emphasized emerging markets as one positive in a challenging environment posed by U.S. healthcare reform and European price cuts and austerity measures. Pharma companies stressed cost-cutting actions such as restructuring their businesses and closing facilities in the U.S. and Europe, while simultaneously discussing increased resource allocation for Asia and other emerging markets.
You may also be interested in...
Lacking Guidelines, HER2 Testing Brings Challenges To Breast Cancer Treatment In China
In a recent report, Kantar Health takes a deep dive into China’s breast cancer market, where cost considerations play a larger role than in the West.
Lacking Guidelines, HER2 Testing Brings Challenges To Breast Cancer Treatment In China
In a recent report, Kantar Health takes a deep dive into China’s breast cancer market, where cost considerations play a larger role than in the West.